Gilead Sciences, Inc. (NEO:GILD)

Canada flag Canada · Delayed Price · Currency is CAD
24.94
-0.25 (-0.99%)
At close: Dec 5, 2025
12.60%
Market Cap 208.49B
Revenue (ttm) 40.51B
Net Income (ttm) 11.30B
Shares Out n/a
EPS (ttm) 8.95
PE Ratio 18.46
Forward PE 14.55
Dividend n/a
Ex-Dividend Date n/a
Volume 4,883
Average Volume 6,130
Open 24.96
Previous Close 25.19
Day's Range 24.80 - 24.96
52-Week Range 20.08 - 26.29
Beta n/a
RSI 44.59
Earnings Date Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 17,600
Stock Exchange Cboe Canada
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

There is no news available yet.